Quarterly ResultAug 10, 2026, 04:14 PM
Palisade Bio Q2 Net Loss $(10.57M), EPS $(0.05); Cash $125.2M
AI Summary
Palisade Bio reported a net loss of $10.57 million, or $(0.05) per share, for Q2 2026, compared to a net loss of $2.78 million, or $(0.58) per share, in Q2 2025. License revenue was $0.5 million for the quarter. The company ended Q2 2026 with $125.2 million in cash and cash equivalents, providing sufficient capital for at least one year. The company also increased its authorized common stock to 450 million shares and is advancing its lead clinical product candidate, PALI-2108, into Phase 2 clinical trials.
Key Highlights
- Q2 2026 Net Loss: $(10.57) million, compared to $(2.78) million in Q2 2025.
- Q2 2026 Basic and Diluted EPS: $(0.05), compared to $(0.58) in Q2 2025.
- Q2 2026 License Revenue: $0.5 million, up from $0 in Q2 2025.
- Cash and cash equivalents as of June 30, 2026: $125.2 million.
- Total assets as of June 30, 2026: $127.3 million.
- Authorized common stock increased from 300 million to 450 million shares.
- Issued 1.54 million common shares for $3.0 million in March 2026.
- PALI-2108 is advancing into Phase 2 clinical trials for inflammatory bowel disease.
Price Impact
More from PALI